Retractable Technologies Inc

Retractable Technologies Inc(RVP)股票分析

$0.569

+0.003 (+0.60%)收盤時

Loading chart…
最高
0.582
開盤
0.578
成交量加權均價
0.57
成交量
51.72K
市值
32.63M
最低
0.562
成交金額
29.53K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors.

AI 分析 of Retractable Technologies Inc (RVP)

賣出

Retractable Technologies Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $0.5694, and the company has reported a significant net loss of $4.2 million in Q1 2026, alongside a 13.3% year-over-year decline in sales. Additionally, the RSI is at 27.179, indicating that the stock is oversold, but this does not outweigh the financial risks. The main risk is the ongoing operational losses, which have widened to $6.2 million, suggesting challenges in achieving profitability.

估值指標

Retractable Technologies Inc(RVP)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 RVP 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%RVP

$0.71

情境價格

基

基準

基準 · 50%RVP

$0.66

情境價格

悲

悲觀

悲觀 · 25%RVP

$0.57

情境價格

RVP 常見問題 —— 由 Alphio AI 解答

Retractable Technologies, Inc. is engaged in the manufacturing and marketing of safety medical products (predominately syringes) for the healthcare industry. The Company is focused on the production of injection devices (syringes and needles). Such products are marketed under the VanishPoint, Patient Safe, and EasyPoint brands. The VanishPoint syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe syringes are designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. The EasyPoint is a retractable needle that can be used with luer lock syringes, luer slip syringes, and prefilled syringes to give injections. The EasyPoint needle can also be used to aspirate fluids and for blood collection. Its products are distributed by various specialty and general line distributors. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Retractable Technologies Inc is not a good buy right now due to its declining financial performance and negative market sentiment. The current price is $0.5694, and the company has reported a significant net loss of $4.2 million in Q1 2026, alongside a 13.3% year-over-year decline in sales. Additionally, the RSI is at 27.179, indicating that the stock is oversold, but this does not outweigh the financial risks. The main risk is the ongoing operational losses, which have widened to $6.2 million, suggesting challenges in achieving profitability.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易